vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and EPR PROPERTIES (EPR). Click either name above to swap in a different company.

EPR PROPERTIES is the larger business by last-quarter revenue ($181.3M vs $156.4M, roughly 1.2× BIOCRYST PHARMACEUTICALS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs 3.6%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 2.3%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

EPR Properties, formerly Entertainment Properties Trust, is a real estate investment trust based in Kansas City, Missouri, that invests in amusement parks, movie theaters, ski resorts, and other entertainment properties. It owns 353 properties as of 2022.

BCRX vs EPR — Head-to-Head

Bigger by revenue
EPR
EPR
1.2× larger
EPR
$181.3M
$156.4M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+3.9% gap
BCRX
7.5%
3.6%
EPR
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
2.3%
EPR

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BCRX
BCRX
EPR
EPR
Revenue
$156.4M
$181.3M
Net Profit
$62.6M
Gross Margin
Operating Margin
13.6%
55.5%
Net Margin
34.5%
Revenue YoY
7.5%
3.6%
Net Profit YoY
845.8%
EPS (diluted)
$0.00
$0.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
EPR
EPR
Q1 26
$156.4M
$181.3M
Q4 25
$406.6M
$182.9M
Q3 25
$159.4M
$182.3M
Q2 25
$163.4M
$178.1M
Q1 25
$145.5M
$175.0M
Q4 24
$131.5M
$177.2M
Q3 24
$117.1M
$180.5M
Q2 24
$109.3M
$173.1M
Net Profit
BCRX
BCRX
EPR
EPR
Q1 26
$62.6M
Q4 25
$245.8M
$66.9M
Q3 25
$12.9M
$66.6M
Q2 25
$5.1M
$75.6M
Q1 25
$32.0K
$65.8M
Q4 24
$-26.8M
$-8.4M
Q3 24
$-14.0M
$46.6M
Q2 24
$-12.7M
$45.1M
Gross Margin
BCRX
BCRX
EPR
EPR
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
EPR
EPR
Q1 26
13.6%
55.5%
Q4 25
64.0%
56.8%
Q3 25
18.6%
53.5%
Q2 25
18.2%
62.5%
Q1 25
14.6%
58.1%
Q4 24
-3.4%
25.5%
Q3 24
6.6%
51.4%
Q2 24
8.0%
45.9%
Net Margin
BCRX
BCRX
EPR
EPR
Q1 26
34.5%
Q4 25
60.5%
36.6%
Q3 25
8.1%
36.5%
Q2 25
3.1%
42.5%
Q1 25
0.0%
37.6%
Q4 24
-20.4%
-4.7%
Q3 24
-12.0%
25.8%
Q2 24
-11.6%
26.1%
EPS (diluted)
BCRX
BCRX
EPR
EPR
Q1 26
$0.00
$0.74
Q4 25
$1.13
$0.80
Q3 25
$0.06
$0.79
Q2 25
$0.02
$0.91
Q1 25
$0.00
$0.78
Q4 24
$-0.13
$-0.19
Q3 24
$-0.07
$0.53
Q2 24
$-0.06
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
EPR
EPR
Cash + ST InvestmentsLiquidity on hand
$259.0M
$68.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3B
Total Assets
$465.1M
$5.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
EPR
EPR
Q1 26
$259.0M
$68.5M
Q4 25
$274.7M
$90.6M
Q3 25
$212.9M
$13.7M
Q2 25
$260.0M
$13.0M
Q1 25
$295.1M
$20.6M
Q4 24
$320.9M
$22.1M
Q3 24
$96.8M
$35.3M
Q2 24
$78.4M
$33.7M
Total Debt
BCRX
BCRX
EPR
EPR
Q1 26
Q4 25
$2.9B
Q3 25
$2.8B
Q2 25
$2.8B
Q1 25
$2.8B
Q4 24
$2.9B
Q3 24
$2.9B
Q2 24
$2.8B
Stockholders' Equity
BCRX
BCRX
EPR
EPR
Q1 26
$2.3B
Q4 25
$-119.2M
$2.3B
Q3 25
$-387.9M
$2.3B
Q2 25
$-421.6M
$2.3B
Q1 25
$-451.9M
$2.3B
Q4 24
$-475.9M
$2.3B
Q3 24
$-468.6M
$2.4B
Q2 24
$-475.6M
$2.4B
Total Assets
BCRX
BCRX
EPR
EPR
Q1 26
$465.1M
$5.7B
Q4 25
$514.2M
$5.7B
Q3 25
$446.4M
$5.5B
Q2 25
$457.2M
$5.6B
Q1 25
$480.0M
$5.5B
Q4 24
$490.4M
$5.6B
Q3 24
$491.3M
$5.7B
Q2 24
$472.4M
$5.6B
Debt / Equity
BCRX
BCRX
EPR
EPR
Q1 26
Q4 25
1.26×
Q3 25
1.19×
Q2 25
1.20×
Q1 25
1.20×
Q4 24
1.23×
Q3 24
1.19×
Q2 24
1.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
EPR
EPR
Operating Cash FlowLast quarter
$113.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.81×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
EPR
EPR
Q1 26
$113.4M
Q4 25
$292.0M
$421.0M
Q3 25
$41.6M
$136.5M
Q2 25
$41.3M
$87.3M
Q1 25
$-27.5M
$99.4M
Q4 24
$-5.2M
$393.1M
Q3 24
$8.2M
$122.0M
Q2 24
$-1.4M
$78.7M
Free Cash Flow
BCRX
BCRX
EPR
EPR
Q1 26
Q4 25
$291.2M
$269.2M
Q3 25
$40.3M
$132.1M
Q2 25
$41.1M
$82.4M
Q1 25
$-27.7M
$84.7M
Q4 24
$-5.9M
$129.2M
Q3 24
$8.2M
$121.5M
Q2 24
$-1.5M
$71.3M
FCF Margin
BCRX
BCRX
EPR
EPR
Q1 26
Q4 25
71.6%
147.1%
Q3 25
25.3%
72.5%
Q2 25
25.2%
46.3%
Q1 25
-19.0%
48.4%
Q4 24
-4.5%
72.9%
Q3 24
7.0%
67.3%
Q2 24
-1.4%
41.2%
Capex Intensity
BCRX
BCRX
EPR
EPR
Q1 26
0.1%
Q4 25
0.2%
82.9%
Q3 25
0.8%
2.4%
Q2 25
0.1%
2.7%
Q1 25
0.1%
8.4%
Q4 24
0.5%
148.9%
Q3 24
0.1%
0.3%
Q2 24
0.1%
4.2%
Cash Conversion
BCRX
BCRX
EPR
EPR
Q1 26
1.81×
Q4 25
1.19×
6.29×
Q3 25
3.23×
2.05×
Q2 25
8.12×
1.15×
Q1 25
-859.91×
1.51×
Q4 24
Q3 24
2.62×
Q2 24
1.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

EPR
EPR

Rental revenue$155.2M86%
Mortgage and other financing income$16.0M9%
Other$10.1M6%

Related Comparisons